查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087655

尿道感染市場：2026-2032年全球市場預測（依治療方法、診斷方法、感染疾病類型、年齡層、感染部位、給藥途徑、病原體類型和最終用戶分類）

Urinary Tract Infection Market by Treatment, Diagnosis Method, Infection Type, Age Group, Infection Site, Route Of Administration, Pathogen Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，尿道感染市場規模將達到 166.2 億美元，複合年成長率為 7.15%。

主要市場統計數據
基準年 2025 102.4億美元
預計年份：2026年 109.6億美元
預測年份 2032 166.2億美元
複合年成長率 (%) 7.15%

尿道感染（UTI）仍然是社區醫療機構、門診診所、長期照護機構和醫院中最常見的細菌感染疾病之一。雖然臨床文獻一致認為大腸桿菌是單純性尿道感染、導尿管相關泌尿尿道感染（ CAUTI）、懷孕相關尿道感染、糖尿病相關尿道感染感染疾病的診斷和治療難度日益增加。

泌尿道感染（UTI）產業的格局受到以下因素的影響：龐大的患者群體、日益嚴重的抗生素抗藥性、對快速診斷的需求、遠距遠端醫療分流的普及以及人們對無抗生素預防泌尿道感染的重新關注。產業領導者正優先考慮合理使用抗生素、即時檢測、分子診斷、疫苗研發、基於微生物組的方法以及數位診療路徑，以改善患者預後並減少不必要的處方箋。

尿路感染產業格局的變革性變化

尿道感染的治療模式正從經驗性治療轉向實證、風險分層治療。抗菌藥物抗藥性是主要促進因素。美國、歐洲和亞洲的監測計畫報告顯示，泌尿道病原體的抗藥性日益增強，尤其是對Fluoroquinolones和產超頻譜BETA-內醯胺酶（ESBL）的腸桿菌屬細菌。這促使人們更加重視培養為基礎的治療、整合區域性抗生素敏感性譜以及快速抗生素敏感性檢測。

人工智慧（AI）在尿道感染（UTI）治療中的累積影響

人工智慧 (AI) 正成為整個尿路感應 (UTI) 價值鏈中一股切實的驅動力。在診斷領域，AI 驅動的尿液檢查解讀、基於影像的顯微鏡檢查和機器學習模型能夠識別污染檢體、預測培養陽性結果，並確定需要進行確診檢測的檢體優先順序。在臨床決策支援方面，演算法可以整合症狀、妊娠狀態、腎功能、既往培養結果、過敏史和區域抗藥性模式等信息，從而提供符合合理抗菌藥物使用策略的處方支持。

尿路感染市場的關鍵區域洞察

在北美，成熟的診斷基礎設施、健全的抗生素使用方案以及遠端醫療在非免疫缺陷型尿道感染管理中的日益普及，促使美國和加拿大的公共衛生機構繼續將抗生素的使用和醫療相關感染的預防放在首位。在歐洲，國家抗生素使用政策、歐洲泌尿系統協會指南、協調一致的抗生素抗藥性監測以及對減少不合理抗生素暴露的廣泛重視，正在塑造著市場格局。在亞太地區，龐大的患者群體、醫療資源的利用率以及對臨床檢查室投入的增加，使得尿路感染的診斷和治療服務日益普及，但尿培養檢測的可及性差異以及抗生素使用方面的差異仍然是持續存在的挑戰。

針對特定族群的尿路感染市場成長的關鍵洞察。

在東協地區，基層醫療的普及、都市化進程、慢性病負擔的加重以及對既適用於集中式檢查室又適用於分散式醫療機構的經濟有效的診斷方法的需求，都在推動尿路感染（UTI）檢測需求的成長。海灣合作理事會（GCC）成員國的特點是醫療保健投入巨大、醫院系統先進，並且越來越關注合理使用抗生素，尤其是在複雜尿路感染、導尿管相關尿道感染（CAUTI）的治療以及三級醫療機構的感染控制方面。歐盟在協調一致的抗生素抗藥性監測、嚴格的監管、基於合理用藥的處方以及基於指南的尿路感染管理方面，仍然是行業標竿。

尿路感染市場主要國家的發展趨勢

在美國，基於遠端醫療的泌尿道感染診療、快速診斷和導尿管相關泌尿道感染（CAUTI）預防計畫需求日益成長，這得益於美國疾病管制與預防中心（CDC）的合理使用抗生素舉措和醫院品質報告機制。在加拿大，人們強調謹慎使用抗生素、獲得基層醫療以及加強監測。同時，墨西哥和巴西的醫療保健系統正致力於解決復發性泌尿道感染和抗生素抗藥性問題，因此，經濟實惠的診斷、標準化的處方流程和擴大的檢測能力都帶來了機會。在英國，國家指南和合理使用抗生素對處方行為有顯著的影響。在德國和法國，先進的診斷技術與系統的報銷機制、檢測網路和監測系統相結合。

為尿路感染產業領導者提供的實用建議

產業領導企業應調整產品策略，使其與合理使用抗生素一致，優先發展能夠減少不必要抗生素暴露並支持標靶治療的診斷和治療方法。企業應投資於快速藥敏試驗、複雜尿道感染的分子檢測以及與電子健康記錄、實驗室資訊系統和區域抗藥性數據整合的數位化臨床決策支援系統。

調查方法

本執行摘要基於權威專家機構的二手研究，包括同行評審的臨床文獻、公共衛生機構、監管指南以及美國疾病管制與預防中心 (CDC)、世界衛生組織 (WHO)、美國國立衛生研究院 (NIH)、美國傳染病學會 (IDSA)、歐洲泌尿外科協會 (EAU) 等機構發布的國家抗菌藥物抗藥性監測計畫和已發表的感染證據。本分析重點檢驗的流行病學數據、臨床實踐趨勢、診斷技術的應用、抗菌藥物抗藥性模式、醫療相關感染的預防以及區域醫療基礎設施指標。

結論

在抗生素抗藥性、復發性行為感染負擔以及醫療資源獲取壓力等因素驅動下，市場需求格局不斷變化，尿道感染市場正朝著更精準化的方向發展。未來的成長將越來越傾向於那些能夠提高診斷準確性、縮短啟動適當治療時間、預防導尿管相關感染疾病以及減少不必要抗生素使用的解決方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章尿道感染市場：依治療方式分類

  • 抗生素
    • 磷黴素
    • 呋喃妥因
    • 複方磺胺甲噁唑
    • 青黴素類
    • 頭孢菌素類抗生素
    • Fluoroquinolones抗生素
  • 非抗生素療法
    • D-甘露糖
    • 益生菌
    • 免疫調節補充劑

第8章：尿道感染市場：依診斷方法分類

  • 尿液檢查
  • 尿液培養
  • 油尺測試
  • 分子診斷
  • 即時檢測

第9章：尿道感染市場：依感染類型分類

  • 單純性膀胱炎
  • 複雜性尿道感染
  • 腎盂腎炎
  • 復發性尿道感染
  • 導尿管相關尿道感染
  • 無症狀性菌尿

第10章：尿道感染市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第11章尿道感染市場：依感染部位分類

  • 下尿道感染
    • 膀胱炎
    • 尿道炎
  • 上尿道感染
    • 腎盂腎炎
    • 輸尿管炎

第12章：尿道感染市場：依給藥途徑分類

  • 口服
  • 靜脈注射
  • 肌肉內注射
  • 膀胱內給藥

第13章：尿道感染市場：依病原體類型分類

  • 細菌病原體
    • 大腸桿菌
    • 克雷伯氏菌屬
    • 變形桿菌屬
    • 銅綠假單胞菌
    • 腸球菌屬
    • 腐生葡萄球菌
  • 真菌病原體
  • 病毒病原體
  • 寄生病原體

第14章尿道感染市場：依最終用戶分類

  • 診所和門診中心
  • 居家照護環境
  • 醫院
  • 診斷檢查室
  • 長期照護機構

第15章：尿道感染市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：尿道感染市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章尿道感染市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbbVie Inc.
  • Almirall, SA
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Bayer AG
  • Beckman Coulter, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Company
  • F Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Merck & Co Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • PhenUtest Diagnostics Ltd.
  • Randox Laboratories Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shionogi & Co, Ltd.
  • Siemens Healthineers AG
  • Sun Pharmaceutical Industries Limited
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd.
  • URIT Medical Electronic Co., Ltd.
  • Viatris Inc
Product Code: MRR-034B50030335

The Urinary Tract Infection Market is projected to grow by USD 16.62 billion at a CAGR of 7.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.24 billion
Estimated Year [2026] USD 10.96 billion
Forecast Year [2032] USD 16.62 billion
CAGR (%) 7.15%

Urinary tract infection (UTI) remains one of the most common bacterial infections across community, outpatient, long-term care, and hospital settings. Clinical literature consistently identifies Escherichia coli as the leading cause of uncomplicated UTI, while recurrent UTI, catheter-associated UTI (CAUTI), pregnancy-related UTI, diabetes-associated UTI, and infections in older adults increase diagnostic and therapeutic complexity.

The UTI industry landscape is shaped by high patient volumes, rising antimicrobial resistance, demand for rapid UTI diagnostics, expanded telehealth triage, and renewed interest in non-antibiotic UTI prevention. Industry leaders are prioritizing stewardship-aligned antibiotics, point-of-care testing, molecular diagnostics, vaccine research, microbiome-based approaches, and digital care pathways that reduce avoidable prescribing while improving patient outcomes.

Transformative Shifts in the UTI Landscape

The urinary tract infection landscape is shifting from empiric treatment toward evidence-based, risk-stratified care. Antimicrobial resistance is the strongest catalyst: surveillance programs in the United States, Europe, and Asia report increasing resistance among uropathogens, especially fluoroquinolone resistance and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. This is accelerating demand for culture-guided therapy, local antibiogram integration, and rapid antimicrobial susceptibility testing.

Care delivery is also transforming. Retail clinics, telemedicine platforms, and home-based sample collection are expanding access for uncomplicated UTI, while hospitals focus on CAUTI prevention bundles, catheter-use reduction, and infection-control analytics. At the same time, women's health investment, aging demographics, diabetes prevalence, and the burden of recurrent UTI are creating demand for preventive solutions beyond traditional antibiotics.

Cumulative Impact of Artificial Intelligence on UTI Care

Artificial intelligence is becoming a practical enabler across the UTI value chain. In diagnostics, AI-supported urinalysis interpretation, image-based microscopy, and machine learning models can help flag contaminated samples, predict culture positivity, and prioritize specimens for confirmatory testing. In clinical decision support, algorithms can incorporate symptoms, pregnancy status, renal function, prior cultures, allergies, and local resistance patterns to support stewardship-aligned prescribing.

AI is also influencing drug discovery and population health. Predictive models can identify patients at higher risk of recurrent UTI or CAUTI, while hospital analytics can monitor catheter days, adherence to prevention bundles, and antibiotic utilization. The greatest commercial impact will come from validated AI tools that demonstrate clinical utility, interoperability with electronic health records, transparent performance across populations, and compliance with medical device and data privacy regulations.

Key Regional Insights Across the UTI Market

North America benefits from mature diagnostic infrastructure, strong antimicrobial stewardship programs, and high adoption of telehealth for uncomplicated UTI management, with U.S. and Canadian public health agencies continuing to emphasize appropriate antibiotic use and healthcare-associated infection prevention. Europe is shaped by national antibiotic stewardship policies, European Association of Urology guidance, coordinated antimicrobial resistance surveillance, and widespread emphasis on reducing inappropriate antibiotic exposure. Asia-Pacific is expanding access to UTI diagnosis and care through large patient populations, rising healthcare utilization, and increasing investments in clinical laboratories, though uneven access to urine culture testing and variable antibiotic use remain persistent challenges.

Latin America is seeing greater demand for affordable UTI diagnostics and standardized treatment pathways as public and private healthcare systems address resistance and recurrent infection burden, particularly in urban centers with expanding laboratory networks. The Middle East is strengthening tertiary-care capacity and infection prevention programs, especially in advanced hospital networks across the region where CAUTI prevention, stewardship, and digital health modernization are policy priorities. Africa faces the dual challenge of underdiagnosis and limited laboratory access in many settings, creating opportunities for low-cost point-of-care diagnostics, surveillance expansion, antimicrobial stewardship education, and practical care pathways suited to resource-variable environments.

Key Group Insights for UTI Market Growth

Within ASEAN, UTI demand is influenced by expanding primary care access, urbanization, rising chronic disease burden, and the need for cost-effective diagnostics that can operate in both centralized laboratories and decentralized care settings. The GCC is characterized by high healthcare investment, advanced hospital systems, and growing attention to antimicrobial stewardship, particularly for complicated UTI, CAUTI management, and infection-control performance across tertiary facilities. The European Union remains a benchmark for coordinated antimicrobial resistance surveillance, regulatory rigor, stewardship-driven prescribing, and guideline-based UTI management.

BRICS countries represent large-volume opportunities driven by population scale, rising diabetes and aging-related risk factors, and expanding diagnostic capacity, but they also face significant resistance-management challenges that require improved surveillance and rational prescribing. G7 markets are differentiated by higher adoption of molecular diagnostics, digital health tools, robust laboratory quality systems, and regulated clinical pathways for outpatient and hospital-based UTI care. NATO-aligned healthcare systems, while diverse, generally emphasize health security, resilient medical supply chains, and preparedness against antimicrobial resistance as a strategic public health threat affecting infection management.

Key Country Insights in the UTI Market

The United States has strong demand for telehealth-enabled UTI care, rapid diagnostics, and CAUTI reduction programs, supported by CDC antimicrobial stewardship initiatives and hospital quality reporting. Canada emphasizes prudent antibiotic use, primary care access, and surveillance, while Mexico and Brazil show opportunities for affordable diagnostics, standardized prescribing, and expanded laboratory capacity as healthcare systems address recurrent UTI and antimicrobial resistance. In the United Kingdom, national guidance and antimicrobial stewardship strongly influence prescribing behavior, while Germany and France combine advanced diagnostics with structured healthcare reimbursement, laboratory networks, and surveillance systems.

Italy and Spain face meaningful recurrent UTI and older-adult care needs, reinforcing demand for prevention strategies and rapid testing. Russia's market is influenced by large population needs, infectious disease surveillance priorities, and evolving access to modern diagnostics. China and India carry substantial UTI volumes and rising resistance concerns, making scalable diagnostics, urine culture access, and stewardship essential for both outpatient and inpatient settings. Japan, South Korea, and Australia have advanced healthcare infrastructure, strong diagnostic quality expectations, and growing interest in prevention strategies for aging populations, recurrent UTI patients, and catheter-associated infection reduction.

Actionable Recommendations for UTI Industry Leaders

Industry leaders should align product strategy with antimicrobial stewardship by prioritizing diagnostics and therapeutics that reduce unnecessary antibiotic exposure and support targeted treatment. Companies should invest in rapid susceptibility testing, molecular panels for complicated UTI, and digital clinical decision support that integrates with electronic health records, laboratory information systems, and local resistance data.

Manufacturers and service providers should segment the UTI market by care setting: telehealth and retail care for uncomplicated UTI, hospital systems for CAUTI prevention and complicated infection, and specialist care for recurrent UTI. Partnerships with laboratories, women's health platforms, payers, public health stakeholders, and health systems can accelerate adoption when solutions demonstrate reduced time to appropriate therapy, fewer repeat visits, lower hospitalization risk, improved patient adherence, and measurable stewardship value.

Research Methodology

This executive summary is based on secondary research from peer-reviewed clinical literature, public health agencies, regulatory guidance, and recognized professional organizations, including CDC, WHO, NIH, IDSA, EAU, national antimicrobial resistance surveillance programs, and published infection-control evidence. The analysis prioritizes validated epidemiology, clinical practice trends, diagnostics adoption, antimicrobial resistance patterns, healthcare-associated infection prevention, and regional healthcare infrastructure indicators.

Insights were synthesized through cross-comparison of guideline updates, surveillance findings, hospital infection-prevention priorities, and technology adoption signals. Market interpretation focuses on evidence-backed drivers rather than unsupported projections, with emphasis on clinical utility, regulatory readiness, reimbursement feasibility, interoperability, stewardship alignment, and operational adoption across outpatient, inpatient, and long-term care environments.

Conclusion

The urinary tract infection market is entering a more precision-oriented phase as antimicrobial resistance, recurrent infection burden, and healthcare access pressures reshape demand. Growth will increasingly favor solutions that improve diagnostic certainty, shorten time to appropriate therapy, prevent catheter-associated infections, and reduce unnecessary antibiotic use.

Organizations that combine validated UTI diagnostics, AI-enabled workflows, stewardship-aligned therapeutics, and patient-centered care models will be best positioned to lead. The strongest opportunities will emerge where clinical evidence, affordability, interoperability, and regional implementation needs are addressed together.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urinary Tract Infection Market, by Treatment

  • 7.1. Antibiotics
    • 7.1.1. Fosfomycin
    • 7.1.2. Nitrofurantoin
    • 7.1.3. Trimethoprim/Sulfamethoxazole
    • 7.1.4. Penicillins
    • 7.1.5. Cephalosporins
    • 7.1.6. Fluoroquinolones
  • 7.2. Non Antibiotic Therapies
    • 7.2.1. D-mannose
    • 7.2.2. Probiotics
    • 7.2.3. Immunomodulatory Supplements

8. Urinary Tract Infection Market, by Diagnosis Method

  • 8.1. Urinalysis
  • 8.2. Urine Culture
  • 8.3. Dipstick Tests
  • 8.4. Molecular Diagnostics
  • 8.5. Point-of-Care Testing

9. Urinary Tract Infection Market, by Infection Type

  • 9.1. Uncomplicated Cystitis
  • 9.2. Complicated Urinary Tract Infection
  • 9.3. Pyelonephritis
  • 9.4. Recurrent Urinary Tract Infection
  • 9.5. Catheter-Associated Urinary Tract Infection
  • 9.6. Asymptomatic Bacteriuria

10. Urinary Tract Infection Market, by Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Urinary Tract Infection Market, by Infection Site

  • 11.1. Lower Tract Infection
    • 11.1.1. Cystitis
    • 11.1.2. Urethritis
  • 11.2. Upper Tract Infection
    • 11.2.1. Pyelonephritis
    • 11.2.2. Ureteritis

12. Urinary Tract Infection Market, by Route Of Administration

  • 12.1. Oral Route
  • 12.2. Intravenous Route
  • 12.3. Intramuscular Route
  • 12.4. Intravesical Route

13. Urinary Tract Infection Market, by Pathogen Type

  • 13.1. Bacterial Pathogens
    • 13.1.1. Escherichia Coli
    • 13.1.2. Klebsiella Species
    • 13.1.3. Proteus Species
    • 13.1.4. Pseudomonas Aeruginosa
    • 13.1.5. Enterococcus Species
    • 13.1.6. Staphylococcus Saprophyticus
  • 13.2. Fungal Pathogens
  • 13.3. Viral Pathogens
  • 13.4. Parasitic Pathogens

14. Urinary Tract Infection Market, by End User

  • 14.1. Clinics & Outpatient Centers
  • 14.2. Homecare Settings
  • 14.3. Hospitals
  • 14.4. Diagnostic Laboratories
  • 14.5. Long-Term Care Facilities

15. Urinary Tract Infection Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Urinary Tract Infection Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Urinary Tract Infection Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbbVie Inc.
  • 19.2. Almirall, SA
  • 19.3. Aspen Pharmacare Holdings Limited
  • 19.4. AstraZeneca PLC
  • 19.5. Bayer AG
  • 19.6. Beckman Coulter, Inc.
  • 19.7. Boehringer Ingelheim International GmbH
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. Cipla Limited
  • 19.10. Dr Reddys Laboratories Ltd.
  • 19.11. Eli Lilly and Company
  • 19.12. F Hoffmann-La Roche AG
  • 19.13. GlaxoSmithKline PLC
  • 19.14. Johnson & Johnson Services, Inc.
  • 19.15. Lupin Ltd.
  • 19.16. Merck & Co Inc.
  • 19.17. Novartis AG
  • 19.18. Novo Nordisk A/S
  • 19.19. Pfizer Inc.
  • 19.20. PhenUtest Diagnostics Ltd.
  • 19.21. Randox Laboratories Ltd.
  • 19.22. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 19.23. Shionogi & Co, Ltd.
  • 19.24. Siemens Healthineers AG
  • 19.25. Sun Pharmaceutical Industries Limited
  • 19.26. Sysmex Corporation
  • 19.27. Teva Pharmaceutical Industries Ltd.
  • 19.28. URIT Medical Electronic Co., Ltd.
  • 19.29. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINARY TRACT INFECTION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL URINARY TRACT INFECTION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FOSFOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FOSFOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FOSFOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NITROFURANTOIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NITROFURANTOIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NITROFURANTOIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRIMETHOPRIM/SULFAMETHOXAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRIMETHOPRIM/SULFAMETHOXAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRIMETHOPRIM/SULFAMETHOXAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON ANTIBIOTIC THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON ANTIBIOTIC THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON ANTIBIOTIC THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL D-MANNOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL D-MANNOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL D-MANNOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOMODULATORY SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNOMODULATORY SUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOMODULATORY SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL URINALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL URINALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL URINE CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL URINE CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL URINE CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIPSTICK TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIPSTICK TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIPSTICK TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UNCOMPLICATED CYSTITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UNCOMPLICATED CYSTITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UNCOMPLICATED CYSTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PYELONEPHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PYELONEPHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PYELONEPHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RECURRENT URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RECURRENT URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RECURRENT URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CATHETER-ASSOCIATED URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CATHETER-ASSOCIATED URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CATHETER-ASSOCIATED URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ASYMPTOMATIC BACTERIURIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASYMPTOMATIC BACTERIURIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ASYMPTOMATIC BACTERIURIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LOWER TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LOWER TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LOWER TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYSTITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CYSTITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYSTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL URETHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL URETHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL URETHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL UPPER TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL UPPER TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL UPPER TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PYELONEPHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PYELONEPHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PYELONEPHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL URETERITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL URETERITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL URETERITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL ROUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORAL ROUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL ROUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRAVENOUS ROUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRAVENOUS ROUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INTRAVENOUS ROUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRAMUSCULAR ROUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INTRAMUSCULAR ROUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRAMUSCULAR ROUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INTRAVESICAL ROUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRAVESICAL ROUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INTRAVESICAL ROUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BACTERIAL PATHOGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BACTERIAL PATHOGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BACTERIAL PATHOGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL KLEBSIELLA SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL KLEBSIELLA SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL KLEBSIELLA SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROTEUS SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PROTEUS SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROTEUS SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENTEROCOCCUS SPECIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ENTEROCOCCUS SPECIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENTEROCOCCUS SPECIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL STAPHYLOCOCCUS SAPROPHYTICUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL STAPHYLOCOCCUS SAPROPHYTICUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL STAPHYLOCOCCUS SAPROPHYTICUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL PATHOGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL PATHOGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL PATHOGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PARASITIC PATHOGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PARASITIC PATHOGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PARASITIC PATHOGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CLINICS & OUTPATIENT CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CLINICS & OUTPATIENT CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CLINICS & OUTPATIENT CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GCC URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. GCC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 262. GCC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 264. GCC URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 265. GCC URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GCC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GCC URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 268. GCC URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 270. GCC URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. GCC URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 273. GCC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. G7 URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. G7 URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 304. G7 URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 305. G7 URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 306. G7 URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 307. G7 URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. G7 URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 309. G7 URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 310. G7 URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 311. G7 URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 312. G7 URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. G7 URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. G7 URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 315. G7 URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. NATO URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. NATO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 318. NATO URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 319. NATO URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 320. NATO URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 321. NATO URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. NATO URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. NATO URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 324. NATO URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 325. NATO URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 326. NATO URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 327. NATO URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. NATO URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 329. NATO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 349. CANADA URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 350. CANADA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. CANADA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 352. CANADA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2018-2032 (USD MILLION)

TABLE 3